{"id":"e6527aa8-0ffa-42a7-9edb-837f1575ad96","companyId":"9dc45318-fb87-4997-a06d-0b54567c6855","modelName":"V1","slug":"vicarious-v1","description":"Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.","formFactor":"surgical","industryVertical":"healthcare","environment":"indoor","maturityStage":"research","lifecycleState":"active","supersededByModelId":null,"specs":{"dof":"9","notes":[{"label":"Verified","value":"Vicarious Surgical (Waltham MA area; went public via SPAC 2021, NYSE: RBOT) is developing the V1 single-port robot. The differentiators (9-DoF human-like instrument, immersive interface) are engineering concepts in animal-lab / design-freeze stage."},{"label":"Current status: DISTRESSED (the headline)","value":"Q1 2026 10-Q carries an EXPLICIT going-concern substantial-doubt. Cash + short-term investments = $3.682M (3/31/2026); runway only through Q2 2026. Q1 2026 net loss $7.329M; ZERO revenue ever (never commercialized). NYSE trading suspended Mar 3 2026, delisting commenced; moved to OTCQB Mar 24 2026. A reverse split was used as a survival maneuver."},{"label":"Maturity = research (gating not even submitted)","value":"NO FDA clearance and NO FDA submission yet (planned De Novo, first-in-human repeatedly delayed). V1 does nothing commercial: no revenue, no installed base, no cleared device. NO clearance = research-tier. At material risk of becoming discontinued within the runway window. RE-VERIFY within weeks given the Q2-2026 cash cliff."},{"label":"Claimed but NOT verified","value":"Any completed first-in-human procedure; a firm/met FDA submission date; that the company remains a going concern past Q2 2026; successful Nasdaq relisting; AI-assist or autonomy (none cleared or commercial; teleoperated by design)."},{"label":"Re-verify 2026-06-03","value":"Distress intact (Q1 2026 10-Q, filed Apr 30 2026: cash + ST investments $3.682M at 3/31/2026, runway through Q2 2026, Q1 net loss $7.329M, accumulated deficit $253.446M, still zero revenue, still NO FDA submission / NO first-in-human). NEW defensive action: applied to UPLIST to the Nasdaq Capital Market + filed a preliminary proxy for a board-authorized reverse stock split (ratio TBD) - both INTENTIONS/applications, NOT completed (does not yet meet Nasdaq initial-listing requirements). No bankruptcy, acquisition, or new financing closed. No lifecycle change; maturity stays research."}],"console":"immersive virtual-reality-style surgeon interface","products":"V1: single-port system with a '9-DoF human-like' instrument and an immersive VR-style surgeon interface ('transport the surgeon inside the patient'). Pre-commercial; no FDA submission yet.","formFactor":"surgical (single-port surgical robot concept: 9-DoF human-like instrument + immersive VR-style surgeon interface)","fda_clearance":"none","visualization":"virtual-reality-style"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.businesswire.com/news/home/20260303-vicarious-surgical-nyse-delisting","title":"Vicarious Surgical receives NYSE delisting notice (Mar 3 2026)","sourceName":"Vicarious Surgical (Business Wire)"},{"url":"https://www.therobotreport.com/vicarious-surgical-faces-nyse-delisting-again/","title":"Vicarious Surgical faces NYSE delisting; moved to OTCQB","sourceName":"The Robot Report"},{"url":"https://www.massdevice.com/vicarious-surgical-timeline-delay/","title":"Vicarious Surgical moves its surgical-robot timeline back again","sourceName":"MassDevice"},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=RBOT","title":"Vicarious Surgical Q1 2026 10-Q (going-concern; $3.682M cash; runway thru Q2 2026)","sourceName":"SEC EDGAR"},{"url":"https://www.sec.gov/Archives/edgar/data/0001812173/000121390026049749/ea0287711-10q_vicarious.htm","title":"Vicarious Surgical Form 10-Q Q1 FY2026 (filed Apr 30 2026): cash + ST investments $3.682M, runway through Q2 2026, accumulated deficit $253.446M, zero revenue","sourceName":"SEC EDGAR"},{"url":"https://www.businesswire.com/news/home/20260316676583/en/Vicarious-Surgical-Announces-Strategic-Plan-to-Pursue-Nasdaq-Listing","title":"Vicarious Surgical announces strategic plan to pursue Nasdaq listing (application + reverse-split proxy; not yet completed)","sourceName":"Business Wire"}],"aliases":["Vicarious V1","Vicarious Surgical System"],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"keyFacts":[{"label":"Autonomy level","value":"teleoperated by design"},{"label":"Maturity","value":"research"},{"label":"Cash and short-term investments","value":"$3.682 million as of March 31, 2026"},{"label":"Runway","value":"through Q2 2026"},{"label":"Q1 2026 net loss","value":"$7.329 million"},{"label":"Accumulated deficit","value":"$253.446 million"},{"label":"Revenue","value":"zero (never commercialized)"},{"label":"FDA clearance","value":"none"},{"label":"FDA submission","value":"none yet"}],"createdAt":"2026-06-03T20:12:38.213Z","updatedAt":"2026-07-12T04:24:54.291Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":null,"autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"jsonLd":{"@context":"https://schema.org","@type":"Product","@id":"https://registry.deploy.report/models/vicarious-v1","url":"https://registry.deploy.report/models/vicarious-v1","name":"V1","alternateName":["Vicarious V1","Vicarious Surgical System"],"description":"Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.","identifier":"e6527aa8-0ffa-42a7-9edb-837f1575ad96","category":"surgical","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"research","lifecycle_state":"active","architectural_position":{"cohort":"surgical","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":6,"primary_source_types":["primary-company-ir","primary-sec-filing","secondary-trade-publication"]}}}